-
Je něco špatně v tomto záznamu ?
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib
Jan Smetana, Kristina Berankova, Romana Zaoralova, Pavel Nemec, Henrieta Greslikova, Renata Kupska, Aneta Mikulasova, Jan Frohlich, Sabina Sevcikova, Lucie Zahradova, Marta Krejci, Viera Sandecka, Martina Almasi, Petra Kaisarova, Hana...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT11154
MZ0
CEP - Centrální evidence projektů
NT12130
MZ0
CEP - Centrální evidence projektů
NT13190
MZ0
CEP - Centrální evidence projektů
NT13492
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Plný text - Článek
Plný text - Článek
Zdroj
Zdroj
Zdroj
- MeSH
- chromozomální aberace MeSH
- dospělí MeSH
- incidence MeSH
- kyseliny boronové terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidské chromozomy, pár 1 * MeSH
- mnohočetný myelom farmakoterapie genetika mortalita patologie MeSH
- prognóza MeSH
- protinádorové látky terapeutické užití MeSH
- pyraziny terapeutické užití MeSH
- recidiva MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- thalidomid terapeutické užití MeSH
- trizomie * MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
UNLABELLED: Chromosomal aberrations are important prognostic factors in multiple myeloma diagnosis. We evaluated the effect common high-risk chromosomal aberrations in a cohort of 102 patients with relapsed disease treated with bortezomib or thalidomide. Our results showed that patients treated with thalidomide with a gain(1)(q21) had inferior survival compared with the bortezomib group. Therefore, bortezomib-based regiments are more effective for patients with relapsed multiple myeloma with an incidence of gain in the gain(1)(q21). BACKGROUND: Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described. PATIENTS AND METHODS: We analyzed the prognostic value of an extended panel of chromosomal aberrations [del(13)(q14), del(17)(p13), t(4;14)(p16;q32), gain(1)(q21), and hyperdiploidy] by using the technique of interphase fluorescence in situ hybridization in a cohort of 102 patients with relapsed MM treated with thalidomide- or bortezomib-based protocols. RESULTS: The gain(1)(q21) had a negative impact on overall survival for patients with MM treated with thalidomide (15.7 vs. 41.3 months; P = .004). Moreover, we confirmed the negative impact of the cumulative effect of 2 or more cytogenetic changes that occur simultaneously on the overall survival in the thalidomide group (20.3 months vs. not yet reached; P = .039). We did not find any significant impact of the aberrations studied on overall survival in the bortezomib cohort of patients. CONCLUSION: We conclude that bortezomib-based protocols are able to partially overcome the negative prognostic impact of the tested chromosomal abnormalities in patients with relapsed MM.
Department of Clinical Hematology University Hospital Brno Czech Republic
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Department of Hematology University Hospital Krakow Poland
Department of Internal Hematooncology University Hospital Brno Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040958
- 003
- CZ-PrNML
- 005
- 20200219092625.0
- 007
- ta
- 008
- 140107s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clml.2012.11.012 $2 doi
- 035 __
- $a (PubMed)23291040
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Smetana, Jan $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $7 xx0128923
- 245 10
- $a Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib / $c Jan Smetana, Kristina Berankova, Romana Zaoralova, Pavel Nemec, Henrieta Greslikova, Renata Kupska, Aneta Mikulasova, Jan Frohlich, Sabina Sevcikova, Lucie Zahradova, Marta Krejci, Viera Sandecka, Martina Almasi, Petra Kaisarova, Hana Melicharova, Zdenek Adam, Miroslav Penka, Jiri Jarkovsky, Arthur Jurczyszyn, Roman Hajek, Petr Kuglik
- 520 9_
- $a UNLABELLED: Chromosomal aberrations are important prognostic factors in multiple myeloma diagnosis. We evaluated the effect common high-risk chromosomal aberrations in a cohort of 102 patients with relapsed disease treated with bortezomib or thalidomide. Our results showed that patients treated with thalidomide with a gain(1)(q21) had inferior survival compared with the bortezomib group. Therefore, bortezomib-based regiments are more effective for patients with relapsed multiple myeloma with an incidence of gain in the gain(1)(q21). BACKGROUND: Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described. PATIENTS AND METHODS: We analyzed the prognostic value of an extended panel of chromosomal aberrations [del(13)(q14), del(17)(p13), t(4;14)(p16;q32), gain(1)(q21), and hyperdiploidy] by using the technique of interphase fluorescence in situ hybridization in a cohort of 102 patients with relapsed MM treated with thalidomide- or bortezomib-based protocols. RESULTS: The gain(1)(q21) had a negative impact on overall survival for patients with MM treated with thalidomide (15.7 vs. 41.3 months; P = .004). Moreover, we confirmed the negative impact of the cumulative effect of 2 or more cytogenetic changes that occur simultaneously on the overall survival in the thalidomide group (20.3 months vs. not yet reached; P = .039). We did not find any significant impact of the aberrations studied on overall survival in the bortezomib cohort of patients. CONCLUSION: We conclude that bortezomib-based protocols are able to partially overcome the negative prognostic impact of the tested chromosomal abnormalities in patients with relapsed MM.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a kyseliny boronové $x terapeutické užití $7 D001897
- 650 _2
- $a chromozomální aberace $7 D002869
- 650 12
- $a lidské chromozomy, pár 1 $7 D002878
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x farmakoterapie $x genetika $x mortalita $x patologie $7 D009101
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a pyraziny $x terapeutické užití $7 D011719
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a thalidomid $x terapeutické užití $7 D013792
- 650 _2
- $a výsledek terapie $7 D016896
- 650 12
- $a trizomie $7 D014314
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Beránková, Kristina, $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $d 1984- $7 xx0182102
- 700 1_
- $a Zaoralová, Romana $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $7 xx0126082
- 700 1_
- $a Němec, Pavel $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $7 xx0162732
- 700 1_
- $a Grešliková, Henrieta $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0122004
- 700 1_
- $a Kupská, Renata $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0128684
- 700 1_
- $a Mikulášová, Aneta $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $7 _AN050306
- 700 1_
- $a Fröhlich, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $7 xx0240724
- 700 1_
- $a Ševčíková, Sabina, $d 1972- $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 mub2015859787
- 700 1_
- $a Zahradova, Lucie $u Department of Internal Hematooncology, University Hospital, Brno, Czech Republic
- 700 1_
- $a Krejčí, Marta, $u Department of Internal Hematooncology, University Hospital, Brno, Czech Republic $d 1969- $7 jx20080512017
- 700 1_
- $a Sandecká, Viera $u Department of Internal Hematooncology, University Hospital, Brno, Czech Republic $7 xx0129325
- 700 1_
- $a Almáši, Martina $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital, Brno, Czech Republic $7 xx0122075
- 700 1_
- $a Májková, Petra $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0157102
- 700 1_
- $a Melicharova, Hana $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Adam, Zdeněk, $u Department of Internal Hematooncology, University Hospital, Brno, Czech Republic $d 1953- $7 jn19981000018
- 700 1_
- $a Penka, Miroslav, $u Department of Clinical Hematology, University Hospital, Brno, Czech Republic $d 1952- $7 nlk19990073680
- 700 1_
- $a Jarkovský, Jiří $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 stk2008461294
- 700 1_
- $a Jurczyszyn, Arthur $u Department of Hematology, University Hospital, Krakow, Poland
- 700 1_
- $a Hájek, Roman, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Internal Hematooncology, University Hospital, Brno, Czech Republic; Department of Clinical Hematology, University Hospital, Brno, Czech Republic $d 1964- $7 nlk20000083645
- 700 1_
- $a Kuglík, Petr, $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $d 1957- $7 ola2003204793
- 773 0_
- $w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 13, č. 2 (2013), s. 123-130
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23291040 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20200219093028 $b ABA008
- 999 __
- $a ok $b bmc $g 1005354 $s 839470
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 13 $c 2 $d 123-130 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
- GRA __
- $a NT11154 $p MZ0
- GRA __
- $a NT12130 $p MZ0
- GRA __
- $a NT13190 $p MZ0
- GRA __
- $a NT13492 $p MZ0
- LZP __
- $a Pubmed-20140107
